Construction of an Innovative Nanogel and Its Applications for Achieving Chemo-Immunotherapy of Tumors

被引:0
|
作者
Wang, Sibei [1 ,2 ]
Nie, Fan [1 ,2 ]
Lin, Zhen [1 ,2 ]
Cao, Ruyu [1 ,2 ]
Xu, Jing [1 ,2 ]
Guo, Yuanqiang [1 ,2 ]
机构
[1] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
[2] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
基金
中国国家自然科学基金;
关键词
nanogels; reduction responsiveness; diosgenin; lentinan; chemotherapy; immunotherapy; DELIVERY-SYSTEM; LENTINAN; THERAPY; POLYSACCHARIDE; DRUG;
D O I
10.1021/acsami.4c13445
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Malignant tumors, also known as cancers, are a global public health problem. Nanogels are promising carriers for the delivery of anticancer medicines. Therefore, based on the unique microenvironment of tumor cells and the advantages of nanogels, a simple and economical one-pot synthesis method was designed to construct natural polysaccharide-based redox-responsive nanogels (LDD NGs). The enhanced permeability and retention (EPR) effect enriched LDD NGs in tumor cells, which then rapidly collapsed and released the natural antitumor drug diosgenin (DG) and the natural polysaccharide lentinan (LNT) via the depletion of a high level of reduced glutathione (GSH) in tumor cells, resulting in a synergistic therapeutic effect of chemotherapy and immunotherapy. In vivo antitumor experiments showed that LDD NGs could inhibit the proliferation and metastasis of the A549 lung cancer cells. Further studies indicated that LDD NGs could increase the production of ROS and induce apoptosis of A549 cells. In addition, LNT released from LDD NGs could promote the proliferation of dendritic cells, increase the production of NO, and upregulate the expressions of the costimulatory molecules CD40, CD80, CD86, and MHC-II. The construction of LDD NGs was a novel drug synthesis approach that could provide fresh ideas for the development of polysaccharide-based redox-responsive drug delivery systems.
引用
收藏
页码:59895 / 59906
页数:12
相关论文
共 43 条
  • [31] A thermo-responsive chemically crosslinked long-term-release chitosan hydrogel system increases the efficiency of synergy chemo-immunotherapy in treating brain tumors
    Chuang, Shun-Hao
    Chen, Kuan-Ju
    Cheng, Yu-Ting
    Chen, Yu-Shuan
    Lin, Shuian-Yin
    Chou, Hsiao-Ying
    Tsai, Hsieh-Chih
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 280
  • [32] FIRST-IN-CHILDREN PHASE 1 TRIAL OF INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS: ANALYSIS OF SAFETY, TOLERABILITY, AND 5-YEAR OUTCOME
    Johnson, Theodore
    Pacholczyk, Rafal
    Aguilera, Dolly
    Al-Basheer, Ahmad
    Bajaj, Manish
    Bandopadhayay, Pratiti
    Berrong, Zuzana
    Bouffet, Eric
    Castellino, Robert
    Dorris, Kathleen
    Eaton, Bree
    Esiashvili, Natia
    Foreman, Nicholas
    Fridlyand, Diana
    Giller, Cole
    Heger, Ian
    Kadom, Nadja
    Kennedy, Eugene
    Manoharan, Neevika
    Martin, William
    McDonough, Colleen
    Parker, Rebecca
    Ramaswamy, Vijay
    Ring, Eric
    Rojiani, Amyn
    Sadek, Ramses
    Smith, Amy
    Smith, Chris
    Vaizer, Rachel
    Yeo, Kee Kiat
    MacDonald, Tobey
    Munn, David
    NEURO-ONCOLOGY, 2022, 24 : 68 - 68
  • [33] A RETROSPECTIVE SINGLE CENTRE ANALYSIS OF SAFETY, TOXICITY AND EFFICACY OF RITUXIMAB (ORIGINAL) AND ITS BIOSIMILAR IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH CHEMO-IMMUNOTHERAPY
    Roy, P. S.
    Sengar, M.
    Menon, H.
    Bagal, B.
    Khattry, N.
    Shridhar, E.
    Gujral, S.
    Laskar, S.
    Rangarajan, V.
    Nair, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 351 - 351
  • [34] Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood-Initial results of UK NCRI Phase II/III GALACTIC trial
    Munir, T.
    Howard, D.
    McParland, L.
    Hockaday, A.
    Oughton, J.
    Messina, F.
    Phillips, D.
    Neilson, J.
    Pemberton, N.
    Paneesha, S.
    Kennedy, B.
    Rawstron, A.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 79 - 79
  • [35] Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood-Initial Results of UK NCRI Phase II/III Galactic Trial
    Munir, Talha
    Hillmen, Peter
    McParland, Lucy
    Cohen, Dena
    Hockaday, Anna
    Oughton, Jamie
    Messina, Fabrizio
    Phillips, David
    Neilson, Jeffrey R.
    Pemberton, Nicholas
    Paneesha, Shankara
    Kennedy, Ben
    Rawstron, Andy
    BLOOD, 2017, 130
  • [36] Comparison of the efficacy and safety of Rituximab (Mabthera (TM)) and its biosimilar (Reditux (TM)) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
    Roy, Partha Sarathi
    John, Shiji
    Karankal, Sadashiv
    Kannan, Sadhana
    Pawaskar, Preeti
    Gawande, Jayanta
    Bagal, Bhausaheb
    Khattry, Navin
    Sengar, Manju
    Menon, Hari
    Gujral, Sumeet
    Nair, Reena
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2013, 34 (04) : 292 - 298
  • [37] Chemo-immunotherapy using saffron and its ingredients followed by E7-NT (gp96) DNA vaccine generates different anti-tumor effects against tumors expressing the E7 protein of human papillomavirus
    Afshin Khavari
    Azam Bolhassani
    Fatemeh Alizadeh
    S. Zahra Bathaie
    Prabha Balaram
    Elnaz Agi
    Rouhollah Vahabpour
    Archives of Virology, 2015, 160 : 499 - 508
  • [38] Chemo-immunotherapy using saffron and its ingredients followed by E7-NT (gp96) DNA vaccine generates different anti-tumor effects against tumors expressing the E7 protein of human papillomavirus
    Khavari, Afshin
    Bolhassani, Azam
    Alizadeh, Fatemeh
    Bathaie, S. Zahra
    Balaram, Prabha
    Agi, Elnaz
    Vahabpour, Rouhollah
    ARCHIVES OF VIROLOGY, 2015, 160 (02) : 499 - 508
  • [39] CHEMO-IMMUNOTHERAPY OF MURINE TUMORS USING INTERLEUKIN-2 (IL-2) AND CYCLOPHOSPHAMIDE - IL-2 CAN FACILITATE OR INHIBIT TUMOR-GROWTH DEPENDING ON THE SEQUENCE OF TREATMENT AND THE TUMOR TYPE
    KEDAR, E
    BENAZIZ, R
    EPSTEIN, E
    LESHEM, B
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1989, 29 (01) : 74 - 78